Citius Pharmaceuticals (CTXR) said late Monday it has completed the pending merger of its oncology subsidiary and blank check firm TenX Keane Acquisition (TENK).
The combined company has been renamed Citius Oncology, with its stock expected to debut on Nasdaq on Aug. 13 under the ticker, "CTOR."
Pursuant to the deal, Citius Pharmaceuticals owns about 90% equity of Citius Oncology.
Price: 0.6798, Change: -0.01, Percent Change: -1.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.